Who owns CG Oncology, Inc., from the filings themselves: stakes over 5% (Schedule 13D/G), the institutional managers reporting the stock each quarter (13F), and the funds holding it (N-PORT).
Investors crossing 5% ownership must disclose it. Schedule 13G filers certify the stake is passive; Schedule 13D is the general form for everyone else — founders, strategic holders, and activists alike. Each entry is the holder's most recent disclosure. Coverage begins with SEC's structured filings from December 18, 2024; a holder appears once they file or amend after that date.
Foresite Capital Fund V, L.P.: 1.2% · 1,079,050 shares — Foresite Capital Management V, LLC: 1.2% · 1,079,050 shares — Foresite Capital Opportunity Fund V, L.P.: 1.0% · 857,550 shares
RTW Investments, LP: 9.7% · 8,514,590 shares — Roderick Wong: 9.7% · 8,514,590 shares
11 more 5% stakes behind a free account
See every investor who has disclosed crossing 5% of CG Oncology, Inc..
Sign up freeEvery institutional manager whose latest 13F reports this stock, largest position first. "% of their portfolio" is the weight inside that manager's own book — how much conviction the position represents; "% of company" is how much of CG Oncology, Inc. they hold. Together these 291 managers report 120.15% of shares outstanding.
| Investor | Position value | Shares | % of their portfolio | % of company | As of |
|---|---|---|---|---|---|
| RTW INVESTMENTS, LP | $605M | 8,514,590 | 5.16% | 9.61% | June 30, 2026 |
| T. Rowe Price Investment Management, Inc. | $470M | 6,616,899 | 0.31% | 7.46% | June 30, 2026 |
289 more institutional holders behind a free account
See every manager reporting CG Oncology, Inc., how much of the company they hold, and how big the position is inside their own portfolio.
Sign up freeFunds disclosing this stock in their monthly N-PORT portfolio, with the position's share of the fund's net assets. Together these 332 funds hold 38.93% of shares outstanding — counted inside the manager totals above, not on top of them, since a fund's shares also appear in its manager's 13F.
| Fund | Position value | % of net assets | % of company | As of |
|---|---|---|---|---|
| T. Rowe Price Capital Appreciation Fund | $183M | 0.26% | 2.90% | June 30, 2026 |
| VANGUARD HEALTH CARE FUND | $173M | 0.47% | 2.92% | April 30, 2026 |
330 more funds behind a free account
See every fund holding CG Oncology, Inc. and what share of its net assets the position represents.
Sign up freeLoading...
